Sunshine M Dwojak1, Neil Bhattacharyya. 1. Department of Otolaryngology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, U.S.A.
Abstract
OBJECTIVES/HYPOTHESIS: Determine the incremental costs associated with head and neck cancer (HNCa) and compare the costs with other common cancers. STUDY DESIGN: Cross-sectional analysis of a healthcare expenditure database. METHODS: The Medical Expenditure Panel Survey is a national survey of US households. All cases of HNCa were extracted for 2006, 2008, and 2010. The incremental expenditures associated with HNCa were determined by comparing the healthcare expenditures of individuals with HNCa to the population without cancer, controlling for age, sex, education, insurance status, marital status, geographic region, and comorbidities. Healthcare expenditures for HNCa were then compared to individuals with lung cancer and colon cancer to determine relative healthcare expenditures. RESULTS: An estimated 264,713 patients (annualized) with HNCa were identified. The mean annual healthcare expenditures per individual for HNCa were $23,408 ± $3,397 versus $3,860 ± $52 for those without cancer. The mean adjusted incremental cost associated with HNCa was $15,852 ± $3,297 per individual (P < .001). Within this incremental cost, there was an increased incremental outpatient services cost of $3,495 ± $1,044 (P = .001) and an increased incremental hospital inpatient cost of $6,783 ± $2,894 (P = .020) associated with HNCa. The annual healthcare expenditures per individual fell in between those for lung cancer ($25,267 ± $2,375, P = .607) and colon cancer ($16,975 ± $1,291, P = .055). CONCLUSIONS: Despite its lower relative incidence, HNCa is associated with a significant incremental increase in annual healthcare expenditures per individual, which is comparable to or higher than other common cancers. In aggregate, the estimated annual costs associated with HNCa are $4.20 billion.
OBJECTIVES/HYPOTHESIS: Determine the incremental costs associated with head and neck cancer (HNCa) and compare the costs with other common cancers. STUDY DESIGN: Cross-sectional analysis of a healthcare expenditure database. METHODS: The Medical Expenditure Panel Survey is a national survey of US households. All cases of HNCa were extracted for 2006, 2008, and 2010. The incremental expenditures associated with HNCa were determined by comparing the healthcare expenditures of individuals with HNCa to the population without cancer, controlling for age, sex, education, insurance status, marital status, geographic region, and comorbidities. Healthcare expenditures for HNCa were then compared to individuals with lung cancer and colon cancer to determine relative healthcare expenditures. RESULTS: An estimated 264,713 patients (annualized) with HNCa were identified. The mean annual healthcare expenditures per individual for HNCa were $23,408 ± $3,397 versus $3,860 ± $52 for those without cancer. The mean adjusted incremental cost associated with HNCa was $15,852 ± $3,297 per individual (P < .001). Within this incremental cost, there was an increased incremental outpatient services cost of $3,495 ± $1,044 (P = .001) and an increased incremental hospital inpatient cost of $6,783 ± $2,894 (P = .020) associated with HNCa. The annual healthcare expenditures per individual fell in between those for lung cancer ($25,267 ± $2,375, P = .607) and colon cancer ($16,975 ± $1,291, P = .055). CONCLUSIONS: Despite its lower relative incidence, HNCa is associated with a significant incremental increase in annual healthcare expenditures per individual, which is comparable to or higher than other common cancers. In aggregate, the estimated annual costs associated with HNCa are $4.20 billion.
Authors: Whitney H Beeler; Emily L Bellile; Keith A Casper; Elizabeth Jaworski; Nicholas J Burger; Kelly M Malloy; Matthew E Spector; Andrew G Shuman; Andrew Rosko; Chaz L Stucken; Steven B Chinn; Aleksandar F Dragovic; Christina H Chapman; Dawn Owen; Shruti Jolly; Carol R Bradford; Mark E P Prince; Francis P Worden; Reshma Jagsi; Michelle L Mierzwa; Paul L Swiecicki Journal: Oral Oncol Date: 2019-12-23 Impact factor: 5.337
Authors: Sean T Massa; Nosayaba Osazuwa-Peters; Eric Adjei Boakye; Ronald J Walker; Gregory M Ward Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-03-01 Impact factor: 6.223
Authors: Mohemmed N Khan; Katrina Hueniken; Mirko Manojlovic-Kolarski; Lawson Eng; Maryam Mirshams; Khaleeq Khan; Colleen Simpson; Michael Au; Geoffrey Liu; Wei Xu; Christopher J Longo; David P Goldstein; Jolie Ringash; Rosemary Martino; Aaron R Hansen; John R de Almeida Journal: Cancer Rep (Hoboken) Date: 2021-08-24